90results about How to "Reduce the ability to invade" patented technology

The invention develops a simplified method for the in-vitro isolation and expansion of umbilical mesenchymal stem cells (MSCs) and confirms that the MSCs obtained by the method have the effects of immunoregulation and inflammation inhibition in the treatment of rheumatoid arthritis.

The invention belongs to the field of biomedicine, relates to a novel target for colorectal cancer metastasis treatment, in particular to application of tiRNA as the target in the metastasis treatmentof the colorectal cancer, and also relates to the tiRNA and an antagonist siRNA and the application using the the tiRNA and the antagonist siRNA to prepare medicines for targeted treatment of colorectal cancer metastasis. The invention discloses the use of the tiRNA as the treatment target for the colorectal cancer metastasis or as a medicament for regulating and treating the colorectal cancer metastasis. The antagonist of 5'-tiRNA has a great clinical value in the preparation of pharmaceutical compositions for treating the colorectal cancer, and provides novel drugs and methods for effectivetreatment of the colorectal cancer.

A method for configuring the eucaryotic expression carrier of cell factor IL-24 includes designing the ascending and descending primers, PCR amplifying begining from the second amino acid in the code at human IL-24 N terminal by using TRAPIL-24 plasmid as template, cutting off target band, purifying it with reagent kit, configuring and determining recombinant plasmid pEGFP-CI-IL-24, respectively enzyme-severing the PCR product and carrier pEGFP by Bgl II and Sal I, purifying them by reagent kit, linking fragment, culturing, cloning, determining and sequencing. The recombinant cell factor Il-24 can be used to treat liver cancer, small intestine cancer and melanoma.

The invention relates to an antiallergic gel nose-protecting medical supply and a making method thereof. The nose-protecting medical supply consists of a nose-shading sheet, antiallergic gel and a natural antipathogenic microorganism biomaterial. The nose-shading sheet consists of a film and a filtering sheet. One surface of the film is sticky. The left side and the right side of the film are provided with a left wing part and a right wing part. One side of the film is provided with a plurality of incision lines. A protruding part is arranged in the center of the film. The filtering sheet is arranged at the position of the protruding part in the center of the film and is tilted upwardly. The film surface of the filtering sheet is smeared with antiallergic gel, while the nose surface of the filtering sheet is smeared with natural antipathogenic microorganism biomaterial. The antiallergic gel nose-protecting medical supply is disposable and decomposable and mist on glasses of a user is prevented. Medical biomaterial in the invention has no toxic or side effect, so the antiallergic gel nose-protecting medical supply is safe for children, pregnant women and drivers and is convenient to use. The antiallergic gel nose-protecting medical supply is made by a simple process, is appropriate in cost, and is environmentally-friendly during production.

The invention discloses an application of MAGE-A9 in the preparation of lung cancer treatment drugs. The MAGE-A9 is a target for non-small cell lung cancer gene therapy, and the drugs are designed against the target. Influences of down-regulation of MAGE-A9 gene expression on NSCLC (non-small cell lung cancer) cell invasion, migration and other biological behaviors are researched in test of in vitro environment, and a result of the researches shows that a specific siRNA sequence can effectively inhibit expression of the MAGE-A9 protein in the NSCLC cell strains SPC-A-1 and NCI-H1975. After the MAGE-A9 expression is inhibited through RNA interference, propagation of the SPC-A-1 and NCI-H1975 cells is slow, apoptosis increases, and the cell migration and invasion ability is reduced. The MAGE-A9 is the target for non-small cell lung cancer gene therapy, and can be widely applied in the preparation of the lung cancer treatment drugs.

The invention relates to an siRNA of PRALR and a use thereof. Starting from a TCONS-00013523 sequence, a complete gene sequence is discovered by 5'-RACE and 3'-RACE technologies and named as PRALR (paclitaxel resistance-associated lncRNA, paclitaxel resistance-associated long-chain non-coding RNA), an expression plasmid and siRNA of the PRALR are constructed, the PRALR is further confirmed to be anovel ovarian cancer drug resistance-associated lncRNA, and the proliferation, migration and invasiveness abilities of ovarian cancer paclitaxel-resistant cells decrease significantly after knockdown. The siRNA designed for the PRALR plays an obvious role in reversing drug resistance and inhibiting the growth of paclitaxel-resistant ovarian cancer cells, is significantly superior to other siRNAsdesigned in the research process, and has great potential for developing paclitaxel-resistant ovarian cancer clinical drugs.

The invention provides an application of hydrogen molecule liquid/gas in preparation of drugs for inhibiting tumor stem cells, belonging to the technical field of preparation of drugs for inhibiting tumor stem cells. By applying the liquid/gas containing hydrogen molecules in preparation of drugs for inhibiting tumor stem cells, the tumor formation capability in tumors is obviously inhibited, the invasion ability of tumor cells is obviously reduced, the expression of surface markers CD133 of tumor stem cells is obviously inhibited, and the expression of differentiation markers is promoted.

The invention discloses a siRNA capable of specifically inhibiting expression of an Eya2 gene as well as a recombinant vector and an application of siRNA in reversing drug resistance of ovarian cancer to paclitaxel and belongs to the technical field of molecular biology and biological medicine. The siRNA comprises a sense strand 5'-UAGUUCUACCAUUUCCUUGUA-3' and an antisense strand 5'-CAAGGAAAUGGUAGAACUAGU-3'. The siRNA can specifically and efficiently inhibit mRNA and protein expression of the Eya2 gene, reduce tumor cell proliferation, accelerate tumor cell apoptosis, reduce tumor cell migration and invasion ability and effectively reverse drug resistance of ovarian cancer cells to paclitaxel. The invention further provides the application of Eya2 siRNA and recombinant vector thereof in preparation of drugs for treating ovarian cancer, prostate cancer, breast cancer, adenocarcinoma cancer, squamous-cell carcinoma, urethra cancer and cervical cancer or reversing drug resistance of ovarian cancer.

The invention provides interfering RNA and a lentivirus vector targeted to the OLFM4 gene and application of the interfering RNA and the lentivirus vector in preparation of drugs used for preventing and treating metastasis of stomach cancer tumors to the abdominal cavity or/and the liver. According to the invention, since the interfering RNA can inhibit in vitro migration and invasion ability of gastric cancer cells and liver metastasis capability of gastric cancer cells, decreased expression of OLFM4 is a potential effective mode for treatment of malignant progression of late gastric cancer. It is further determined that an NF-kB signal is an upstream regulation transcription factor of expression of OLFM4 and the interfering RNA has NF-kB signal feeding back and regulating functions.

The invention discloses siRNA capable of specially inhibiting expression of an LAMB1 gene, a recombinant vector of the siRNA and application of the siRNA in reversing ovarian cancer taxol resistance, and belongs to the technical field of molecular biology and biological medicine. The siRNA comprises a sense strand and an antisense strand, the sense strand is 5'-UGUUUGAAAGCCGAAUCUGCG-3', and the antisense strand is 5'-CAGAUUCGGCUUUCAAACAAA-3'. According to the siRNA, mRNA and protein expression of the LAMB1 gene in a cancer cell can be inhibited specially and efficiently, proliferation of the cancer cell is reduced, cell apoptosis is increased, the invasiveness and migration capability of the cancer cell is reduced, and moreover, the resistance of an ovarian cancer cell to taxol can be reversed effectively. The invention further provides the application of the siRNA and the recombinant vector thereof in preparing medicines treating an ovarian cancer, a hepatocellular cancer, a colorectal cancer, a malignant glioma, a prostatic cancer or a gastric cancer and medicines reversing the ovarian cancer taxol resistance.

The invention discloses siRNA [small interfering RNA(ribonucleic acid)] for specifically suppressing expression of PADI2 (protein-arginine deiminase type-2) genes, a recombinant vector with the siRNA and application of the siRNA to reversing taxol resistance of ovarian cancer, and belongs to the technical field of molecular biology and biomedicines. The siRNA comprises positive-sense strands 5'-AAUGUACAGAACUAUCUCGUA-3' and antisense strands 5'-CGAGAUAGUUCUGUACAUUUC-3'. The siRNA, the recombinant vector and the application have the advantages that expression of mRNA (messenger RNA) and proteins of the PADI2 genes can be specifically and efficiently suppressed by the siRNA, cell proliferation can be reduced, cell apoptosis can be increased, the migration and invasion capacity of cells can be deteriorated, and the taxol resistance of ovarian cancer cells can be effectively reversed; the PADI2 siRNA and the recombinant vector can be applied to preparing medicines for treating ovarian cancer, breast cancer, cervical squamous cell carcinoma, colon cancer, liver cancer and lung cancer or reversing medicine resistance of ovarian cancer.

The invention discloses a breast cancer cell line with low expression of HK2 and siRNA used by the breast cancer cell line. The siRNA is oligo-nucleic acid siRNA1 (small interfering ribonucleic acid 1); the oligo-nucleic acid siRNA1 is composed of a single-stranded RNA molecule as shown in SEQ ID NO: 1 and a single-stranded RNA molecule as shown in SEQ ID NO: 2; and a 3' terminal of the oligo-nucleic acid siRNA1 is modified by two dT. Experiments prove that the oligo-nucleic acid siRNA1 can be used for inhibiting the growth of breast cancer tumors, inhibiting the proliferation of breast cancer cells, reducing the invasion ability of the breast cancer cells, reducing the glycolysis ability of the breast cancer cells and constructing a breast cancer cell model with low expression of the HK2. The cell line has an important application value.

The invention discloses an application of Hsa-miR-503 (Human Serum Albumin-Micro Ribonucleic Acid-503) in preparation of a drug for treating a glioma. An MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) method, a flow cytometry and a Transwell experiment show that Hsa-miR-503 can effectively reduce proliferation, migration and invasion abilities of glioma cells and increase apoptosis of the glioma cells; qPCR (Quantitative Polymerase Chain Reaction) detection shows that Hsa-miR-503 has low expression in a glioma tissue or a cell line. The results indicate that Hsa-miR-503 can be used for preparing the drug for treating the glioma, and an expression level of Hsa-miR-503 can serve as a diagnostic index of the glioma. The drug for treating the glioma comprises Hsa-miR-503 and/or a precursor of Hsa-miR-503. A detection reagent kit of Hsa-miR-503 comprises a real-time fluorescent quantitation PCR (Polymerase Chain Reaction) reagent, miR-503, as well as a forward primer and a reverse primer of an internal reference. The application provides a new direction for diagnosis and treatment of the glioma.

The invention discloses siRNA which specifically inhibits PRV1 gene expression and a recombinant vector and application thereof in the reversal of paclitaxel resistance in ovarian cancer, and belongsto the technical field of molecular biology and biomedicine. The siRNA includes sense and antisense strands: the sense strand: 5'-UUCUUAGGGGUCCAUUGCCGG-3'; the antisense strand: 5'-GGCAAUGGACCCCUAAGAACA-3'. The siRNA provided by the invention can specifically and effectively inhibit mRNA and protein expression of PRV1 gene in tumor cells, reduce tumor cell proliferation, increase cell apoptosis, reduce migration and invasion ability of the tumor cells, and can effectively reverse drug resistance of ovarian carcinoma cells to paclitaxel. The invention also provides application of the siRNA andthe recombinant vector thereof in the preparation of a medicament for treating ovarian cancer, gastric cancer, colorectal cancer, neuroblastoma or reversing drug resistance of ovarian cancer.

The invention discloses an interference Rab23 gene of siRNA. The siRNA is hairpin RNA (ribonucleic acid) formed aiming to a target sequence of the Rab23 gene; the siRNA is double-strand siRNA, wherein one strand of nucleotide sequence is shown as SEQ. ID. NO.1 or SEQ. ID. NO.2; the expression of the Rab23 protein is positive correlation with the development of skin scale cancer and is especially related with invasion ability of the skin scale cancer; and the invasion ability of skin scale cancer cells is enabled to lowered by the expression of the interference Rab23 protein. The invention also discloses applications of interference shRNA of the Rab23 gene target sequence in preparing a skin scale cancer resisting drug.

Biological recombinant miR124-3p capable of effectively suppressing osteosarcoma growth is disclosed and has a nucleotide sequence shown as SEQ ID NO:1. A base sequence capable of expressing mature miR124-3p is inserted from an anticodon in the base sequence of human-derived tRNA adopted as a carrier skeleton, then the synthesized structure is transferred into common E. coli through a plasmid, andafter about 12 h of incubation, a target recombinant miRNA is subjected to separation, purification and desalting treatment to obtain the recombinant miRNA that can be put into use directly. Under the premise of ensuring a high yield and high purity, the whole preparation process adopts natural organisms as media, and original biological characteristics of natural miR124-3p in cells are preservedwith extremely high fidelity, and therefore, the miR124-3p is safer, stabler and more natural than miRNA analogues artificially chemically synthesized.

The invention relates to new application of a traditional Chinese medicine, in particular to application of total glycoside of paeonia in preparation of a medicament for treating thyroid cancer and improving tumor radiotherapy synergy, and belongs to the technical field of traditional Chinese medicines. The invention relates to the application of total glycoside of paeonia in preparation of a medicament for treating thyroid cancer and improving tumor radiotherapy synergy. The total glucosides of paeonia can be used as an active ingredient, are added with pharmaceutically-acceptable pharmaceutical excipients or carriers, and are prepared into a preparation according to a method recorded in pharmacy. The total glycosides of paeonia of the invention can also be used as one of the active ingredients, also contain other medicines, are added with pharmaceutically-acceptable pharmaceutical excipients or carriers, and are prepared into a preparation according to the method recorded in pharmacy. Through research, the inventor discovers that: the total glucosides of paeonia have obvious functions of resisting thyroid cancer and enhancing iodine uptake of cancer cells, and can improve the sensitivity of radiotherapy, can be prepared into a medicament for treating thyroid cancer, and can be prepared into a medicament for improving tumor radiotherapy synergy.